Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Wednesday the successful transfer of BIO101 (20-hydroxyecdysone) production to industrial scale by its partner Seqens.

This first GMP-compliant batch of BIO101 (20-hydroxyecdysone), a potential treatment for respiratory decline in Duchenne Muscular Dystrophy (DMD) patients, is now available for Biophytis' clinical programme.

DMD is a severe, progressive muscle wasting disease primarily affecting boys. BIO101 (20-hydroxyecdysone) has the potential to improve respiratory function and quality of life in non-ambulatory DMD patients.

Biophytis, with orphan drug designation for DMD in Europe and the United States, is seeking partners and funding to launch a Phase 1-2 clinical trial to assess pharmacokinetics, safety and efficacy of BIO101 (20-hydroxyecdysone) in this patient population.